CalliSpheres载药栓塞微球加载表柔比星治疗不可切除原发性肝癌的疗效

Clinical efficacy of CalliSpheres drug-eluting beads loaded with epirubicin in the treatment of unresectable primary liver cancer

目的 探讨CalliSpheres载药栓塞微球加载表柔比星在不可切除原发性肝癌(PLC)中的疗效。方法 选取2016年2月至2020年10月铜陵市人民医院收治的104例不可切除PLC患者为研究对象,以随机数字表法分为研究组、对照组,每组各52例。对照组采用常规动脉化疗栓塞(TACE)表柔比星,研究组采用CalliSpheres载药微球加载表柔比星的TACE。治疗后3个月观察效果,并随访12个月。记录患者抗肿瘤疗效、血液肿瘤标志物、肝功能、并发症情况,统计患者预后情况。结果 研究组客观缓解率、临床控制率高于对照组(P<0.05)。治疗后两组患者的甲胎蛋白(AFP)、碱性成纤维细胞生长因子(BFGF)、核因子κB(NF-κB)均低于治疗前(P<0.05),研究组治疗后的AFP、BFGF、NF-κB均低于对照组(P<0.05)。治疗前后两组患者的天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)、总胆红素(TBil)、白蛋白(Alb)水平对比差异均无统计学意义(均P>0.05)。两组总不良事件发生率对比差异无统计学意义(P>0.05)。研究组存活33例,对照组存活22例,差异有统计学意义(P<0.05)。结论 CalliSpheres载药栓塞微球加载表柔比星治疗不可切除PLC疗效显著,安全性及预后良好。

ObjectiveTo explore the efficacy of CalliSpheres drug-eluting beads(DEB)loaded with epirubicin in treating unresectable primary liver cancer(PLC).MethodsA total of 104 patients with unresectable PLC,who were admitted to the Tongling Municipal People's Hospital of China between February 2016 and October 2020 to receive treatment,were enrolled in this study.By using random digital table method,the patients were randomly and equally divided into study group and control group with 52 patients in each group.Conventional transcatheter arterial chemoembolization(TACE)using epirubicin was adopted for the patients of the control group,while TACE using DEB loaded with epirubicin was employed for the patients of the study group.Three months after treatment,the clinical effect was assessed,and the patients were followed up for 12 months.The anti-tumor efficacy,blood tumor markers,liver function,and complications were recorded.The patient prognosis of both groups was calculated.ResultsThe objective remission rate(ORR)and clinical control rate in the study group were higher than those in the control group(P<0.05).The postoperative levels of alpha-fetoprotein(AFP),basic fibroblast growth factor(BFGF),and nuclear factor kappa B(NF-κB)were lower than preoperative ones in both groups(P<0.05),and the postoperative levels of AFP,BFGF and NF-κB in the study group were lower than those in the control group(P<0.05).No statistically significant differences in the preoperative and postoperative levels of aspartate aminotransferase(AST),alanine aminotransferase(ALT),total bilirubin(TBil)and albumin(Alb)existed between the two groups(all P>0.05).There was no statistically significant difference in the incidence of total adverse events between the two groups(P>0.05).Thirty-three patients in the study group and 22 patients in the control group survived,the difference between the two groups was statistically significant(P<0.05).ConclusionFor the treatment of unresectable PLC,TACE using DEB loaded with epirubicin is remarkably effective,safe with good prognosis.